Skip to content
Bomb Report – Lifestyle
Author:
Global Down Syndrome Foundation
Denver Teen with Down Syndrome Stars in Award-Winning Film Debuting on Netflix During Father’s Day Weekend
June 11, 2026
Zepbound (tirzepatide) and Shaquille O’Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
June 10, 2026
Lilly’s oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
June 9, 2026
Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
June 8, 2026
Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
June 8, 2026
GLOBAL Down Syndrome Foundation Celebrates Historic Bipartisan Advancement of the DeOndra Dixon INCLUDE Project Act
May 29, 2026
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association’s 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
May 28, 2026
Foundayo and Zepbound now covered for millions of Americans
May 28, 2026
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
May 22, 2026
GLOBAL’s AcceptAbility Gala Raises $430,000 for Down Syndrome Research and Medical Care as Celebrities and Congressional Leaders Rally Behind the Cause
May 21, 2026
1
2
3
Next Page
→